Imprimir Ver referencias Citación Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy. AMA Citation Dougherty B, Chan A. Dougherty B, & Chan A Dougherty, Brian, and Alex Chan. Association of potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures. 2 Minute Medicine, 28 enero 2021. McGraw Hill, 2021. AccessMedicina. https://accessmedicina.mhmedical.com/updatesContent.aspx?gbosid=555233§ionid=253541094APA Citation Dougherty B, Chan A. Dougherty B, & Chan A Dougherty, Brian, and Alex Chan. (2021). Association of potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures. (2021). 2 minute medicine. McGraw Hill. https://accessmedicina.mhmedical.com/updatesContent.aspx?gbosid=555233§ionid=253541094.MLA Citation Dougherty B, Chan A. Dougherty B, & Chan A Dougherty, Brian, and Alex Chan. "Association of potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures." 2 Minute Medicine McGraw Hill, 2021, https://accessmedicina.mhmedical.com/updatesContent.aspx?gbosid=555233§ionid=253541094. Descargar archivo de la citación: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Annotate Clip Autosuggest Results Association of potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures by Brian Dougherty, Alex Chan Listen +Originally published by 2 Minute Medicine® (view original article). Reused on AccessMedicine with permission. +1. Among a large cohort of Danish adults, the use of potent or very potent topical corticosteroids was found to be associated with an increased risk of osteoporosis and major osteoporotic fracture. +Evidence Level Rating: 2 (Good) +It is well established that in their systemic and inhaled forms, corticosteroids have a negative impact on bone remodeling, increasing the risk of fracture and osteoporosis when given continuously or in high doses. The use of topical corticosteroids (TCSs) can also have negative systemic effects; however, whether their use increases the risk of osteoporosis and major osteoporotic fracture (MOF) is largely unknown. This nationwide retrospective cohort study from Denmark included 723,251 adults (mean [SD] age = 52.8 [19.2] years, 52.8% female) treated with either potent or very potent TCSs. Filled prescription data were converted in equipotent doses to mometasone furoate (1 mg/g). Included participants were treated with the equivalent of at least 200 g of mometasone. The primary outcome was a diagnosis of osteoporosis or MOF. 25.8% of participants were exposed to 500-999 g of mometasone; 15.4% to 1,000-1,999 g; 13.0% to 2,000-9,999 g; and 1.9% to at least 10,000 g. After adjustment, exposure (≥ 500 g vs. 200-499 g) to potent or very potent TCSs was significantly associated with an increased risk of both osteoporosis (HR 1.08, 95% CI 1.05 to 1.11) and MOF (HR 1.05, 95% CI 1.03 to 1.07). The risk of both osteoporosis and MOF was found to increase in a dose-dependent manner. In all, the population-attributable risk was found to be 4.3% (95% CI 2.7% to 5.8%) for osteoporosis and 2.7% (95% CI 1.7% to 3.8%) for MOF. This study demonstrated that the use of high cumulative amounts of potent or very potent TCSs was associated with an increased risk of both osteoporosis and MOF. Given the widespread use of TCSs worldwide, such findings are of public health importance and should help inform new treatment strategies. +Click to read the study in JAMA Dermatology +©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.